<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; POZN</title>
	<atom:link href="http://www.stockbloghub.com/tag/pozn/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NBIX) Focus Turns To Biotech Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740</link>
		<comments>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740#comments</comments>
		<pubDate>Tue, 11 Jan 2011 23:46:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DATA]]></category>
		<category><![CDATA[DATATRAK International Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[GTF]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[Neurocrine Biosciences Inc]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64740</guid>
		<description><![CDATA[Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology  industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel. The event is attended by the “Who’s Who” of the healthcare industry, with currently over 350 companies registered to attend. Two smaller conferences will also take place next week concurrent with the massive J.P. Morgan conference, the 4th annual OneMed Forum 2011 held at the Sir Francis Drake Hotel and the Biotech Showcase 2011 held at the Parc 55 Wyndham Hotel feature smaller companies from the biotech and medical device industries. These conferences are an outstanding opportunity for biotech investors to meet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen’s Announces That FDA Approves Vimovo</title>
		<link>http://www.stockbloghub.com/2010/05/03/pozn-pozen%e2%80%99s-announces-that-fda-approves-vimovo/35915</link>
		<comments>http://www.stockbloghub.com/2010/05/03/pozn-pozen%e2%80%99s-announces-that-fda-approves-vimovo/35915#comments</comments>
		<pubDate>Mon, 03 May 2010 21:39:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35915</guid>
		<description><![CDATA[On April 30, 2010, Pozen (POZN) and its partner, AstraZeneca (AZN), announced that the U.S. Food and Drug Administration (FDA) has approved Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Based on FDA approval, Pozen has earned a $20 million milestone payment from AstraZeneca. We expect that this milestone will be recognized in full in the second quarter 2010. AstraZeneca should be in position to launch Vimovo early in the third quarter 2010. Pozen is entitled to a 10% royalty on net Vimovo sales. AstraZeneca submitted a Marketing Authorization Application (MAA) to the European Medicines Association ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/03/pozn-pozen%e2%80%99s-announces-that-fda-approves-vimovo/35915/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen Remains a Top Pick</title>
		<link>http://www.stockbloghub.com/2010/03/03/pozn-pozen-remains-a-top-pick/29578</link>
		<comments>http://www.stockbloghub.com/2010/03/03/pozn-pozen-remains-a-top-pick/29578#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:29:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29578</guid>
		<description><![CDATA[Pozen (POZN) remains one of our top picks in the small-to-mid cap biotechnology industry.  We view the company as financially sound, exiting 2009 with over $46 million in cash on hand and another potential $20 million coming in April 2010 from AstraZeneca (AZN) for the U.S. approval of Vimovo. The company is also well diversified, with one product on the market in Treximet, one product nearing FDA approval in Vimovo, and one product in phase III trials in PA-325. All three products offer significant catalysts in the near-term. Sales of Treximet in the fourth quarter 2009 totaled $22.7 million at GlaxoSmithKline (GSK). This resulted in a royalty payment from Glaxo to Pozen of approximately $1.1 million. Treximet sales have been tracking below our expectations since the launch almost two years ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/pozn-pozen-remains-a-top-pick/29578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen Initiates New Phase III Trial</title>
		<link>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047</link>
		<comments>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047#comments</comments>
		<pubDate>Fri, 20 Nov 2009 23:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21047</guid>
		<description><![CDATA[This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen Brings Good Data &amp; Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/28/pozn-pozen-brings-good-data-earnings/19030</link>
		<comments>http://www.stockbloghub.com/2009/10/28/pozn-pozen-brings-good-data-earnings/19030#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:32:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19030</guid>
		<description><![CDATA[Vimovo Demonstrates Benefit Over Naproxen Yesterday, at the American College of Gastroenterology meeting in San Diego, Pozen (POZN) released data from two phase III trials comparing Vimovo (formerly PN400) to enteric-coasted naproxen (ECN) in patients with osteoarthritis (OA), rheumatoid arthritis [RA] and ankylosing spondylitis (AS) who are at risk of developing NSAID-associated gastric ulcers. The data demonstrated that patients taking Vimovo experienced significantly greater reduction in severity of dyspepsia (SODA) and overall treatment evaluation for dyspepsia (OTE-DP) compared to patients taking ECN. The OTE-DP results showed 43-46% of the patients on Vimovo reporting positive change at month six vs. only 28-34% on ECN. The results were highly statistically significant. Plus, patients taking Vimovo also had discontinuation rates far below ECN, at 3-5% vs. 11-12%, respectively. The safety of Vimovo was also superior to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/pozn-pozen-brings-good-data-earnings/19030/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen, Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/10/20/pozn-pozen-incorporated-bull-of-the-day/18171</link>
		<comments>http://www.stockbloghub.com/2009/10/20/pozn-pozen-incorporated-bull-of-the-day/18171#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:31:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18171</guid>
		<description><![CDATA[Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low. We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August. We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall. The company is financially well positioned and fundamentally strong with respect to the pipeline. We recommend being buyers at this level. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/pozn-pozen-incorporated-bull-of-the-day/18171/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen, Inc. &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/10/12/pozn-pozen-inc-bull-of-the-day/17400</link>
		<comments>http://www.stockbloghub.com/2009/10/12/pozn-pozen-inc-bull-of-the-day/17400#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:23:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17400</guid>
		<description><![CDATA[Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low. We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August. We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall. The company is financially well positioned and fundamentally strong with respect to the pipeline. We recommend being buyers at this level. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/pozn-pozen-inc-bull-of-the-day/17400/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen Inc.: Stock of the Day</title>
		<link>http://www.stockbloghub.com/2009/02/01/pozn-pozen-inc-stock-of-the-day/2464</link>
		<comments>http://www.stockbloghub.com/2009/02/01/pozn-pozen-inc-stock-of-the-day/2464#comments</comments>
		<pubDate>Sun, 01 Feb 2009 21:19:45 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Pozen Incorporated]]></category>
		<category><![CDATA[POZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2464</guid>
		<description><![CDATA[by Katharine Schildt, Assistant Editor, The Oxford Club This Small-Cap Biotech Just Hit its Stride One of the most recession-proof industries is health care. No matter what happens to the economy people will always need medical attention &#8211; and new developments will always be in the works. On Thursday, a small-cap pharmaceutical company, Pozen, Inc. (Nasdaq: POZN), soared after the Food and Drug Administration agreed to allow testing of two of its experimental drugs. The stock is up over 50% in a week. Yesterday (Thursday), it was one of the top-five percentage gainers on the Nasdaq. Pozen Inc. - Helping Those With Chronic Pain Pozen is a drugmaker that creates new medicines to help patients with diseases that cause chronic pain. Its goal is to improve these patients’ quality of life by providing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/01/pozn-pozen-inc-stock-of-the-day/2464/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

